$KALA
KALA focused on the development and commercialization of therapeutics using proprietary AMPPLIFY mucus-penetrating particle, or MPP, drug delivery technology, with an initial focus on the treatment of eye diseases
INVELTYS - approved by FDA on August 22, 2018. US launch in January 2019
KPI121 0.25% - on PH3 (Third trail on-going), Top line results expected in Q4 2019
Cash - 170M$ (31.12.2018)
2018 Net Loss - 66M$
MKT Cap - 286M$
INVELTYS - approved by FDA on August 22, 2018. US launch in January 2019
KPI121 0.25% - on PH3 (Third trail on-going), Top line results expected in Q4 2019
Cash - 170M$ (31.12.2018)
2018 Net Loss - 66M$
MKT Cap - 286M$
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.